Composite MET-PET Fusion 3.0 Tesla MRI is a New Sensitive Method for the Detection of GH Secreting Adenomas with Abnormal GH Secretary Dynamics
|Shunsuke Satoh1, Hidetoshi Ikeda1*, Toshiyuki Saginoya2 and Kazuo Watanabe3|
|1Reseach Institute for Pituitary Disease, Southern Tohoku General Hospital, Koriyama, Fukushima 963-8563, Japan|
|2Department of Radiology, Southern Tohoku General Hospital, Koriyama, Fukushima 963-8563, Japan|
|3Reseach Institute for Neuroscience, Southern Tohoku General Hospital, Koriyama, Fukushima 963-8563, Japan|
|Corresponding Author :||Hidetoshi Ikeda
Research Institute for Pituitary Disease
Southern Tohoku Research Institute for Neuroscience
7-115 Yatsuyamada, Koriyama
Fukushima 963-8563, Japan
E-mail: [email protected]
|Received September 21, 2012; Accepted November 25, 2012; Published November 29, 2012|
|Citation: Satoh S, Ikeda H, Saginoya T, Watanabe K (2012) Composite MET-PET Fusion 3.0 Tesla MRI is a New Sensitive Method for the Detection of GH Secreting Adenomas with Abnormal GH Secretary Dynamics. J Metabolic Synd S2:005. doi:10.4172/2167-0943.S2-005|
|Copyright: © 2012 Satoh S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.|
Objective: To evaluate the usefulness of methionine (MET)-Positron Emission Tomography (PET) for the early diagnosis of Growth Hormone (GH) secreting adenomas, we retrospectively analyzed patients with abnormal GH dynamics and a histologically confirmed GH secreting pituitary adenoma who underwent pre-operative fluorodeoxyglucose-/MET-PET.
Materials and methods: Thirty-two patients with abnormal GH dynamics were included in this study. 3 Tesla (3T) -MRI, [18F]-flurodeoxyglucose (FDG) -/[11C]-MET-PET, and transsphenoidal surgery were performed in all the patients. We determined correlations among FDG-/MET-PET (maximum standardized uptake value (SUVmax)), serum GH and IGF-1 levels, the GH response to a 75 g Oral Glucose Tolerance Test (OGTT), Thyrotropin-Releasing Hormone (TRH) /Luteinizing Hormone-Releasing Hormone (LHRH) loading tests, tumor volume, and proliferative activity.
Results: The diagnostic sensitivity for early GH secreting adenoma was highest for MET-PET (100%), followed by TRH/LHRH (80%), 75 g OGTT (67%), and FDG-PET (47%). Significant correlations were observed between: MET-PET SUVmax and FDG-PET SUVmax (p<0.01), MET-/FDG-PET SUVmax and tumor volume (MET: p<0.01; FDG: p<0.01) ; MET-/FDG PET SUVmax and MIB-1 labeling index (MET: p<0.01; FDG: p=0.01) ; GH/insulin-like growth factor (IGF)-1 levels and tumor volume (GH: p=0.01; IGF-1: p<0.01) ; and GH and IGF-1 levels (p<0.01).
Conclusions: All the patients with abnormal GH dynamics detected by MET-PET had GH adenomas, indicating that MET-PET is useful for the early diagnosis of GH adenomas.